AIM ImmunoTech Inc. (NYSE:AIM) CEO Thomas K. Equels Purchases 61,729 Shares

AIM ImmunoTech Inc. (NYSE:AIM) CEO Thomas K. Equels purchased 61,729 shares of AIM ImmunoTech stock in a transaction that occurred on Monday, May 6th. The shares were bought at an average price of $0.41 per share, for a total transaction of $25,308.89. Following the completion of the transaction, the chief executive officer now owns 778,184 shares in the company, valued at $319,055.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

AIM ImmunoTech Stock Performance

NYSE AIM opened at $0.43 on Thursday. AIM ImmunoTech Inc. has a one year low of $0.32 and a one year high of $0.75. The company has a market capitalization of $21.57 million, a price-to-earnings ratio of -0.71 and a beta of -0.11. The stock has a 50-day moving average of $0.43 and a 200 day moving average of $0.44.

AIM ImmunoTech (NYSE:AIM) last posted its earnings results on Friday, March 29th. The company reported ($0.26) EPS for the quarter. AIM ImmunoTech had a negative net margin of 14,337.62% and a negative return on equity of 121.69%. The firm had revenue of $0.07 million for the quarter.

About AIM ImmunoTech

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).